Celldex is developing targeted therapeutics to address devastating diseases for which available treatments are inadequate. Our pipeline includes antibodies, antibody-drug conjugates and other protein-based therapeutics derived from a broad set of complementary technologies which have the ability to engage the human immune system and/or directly inhibit tumors to treat specific types of cancer or other diseases.

View all →   RSSRecent Releases
Mar 7, 2018 Celldex Provides Corporate Update and Reports Full Year 2017 Results
Mar 2, 2018 Celldex to Report Fourth Quarter and Year-End 2017 Business/Financial Results and Present at Upcoming Investor Conference
More →Upcoming Events
Details on upcoming events are not yet available.
Featured Financial Reports
Filing Date Title Type Size
Nov 7, 2017 Form 10-Q View HTML View PDF 375.0 KB Add to Briefcase
Mar 7, 2018 Form 10-K View HTML View PDF 1.6 MB Add to Briefcase
Add to Briefcase = add file to Briefcase